SG11201803781XA - Treatment of retinal degeneration using progenitor cells - Google Patents

Treatment of retinal degeneration using progenitor cells

Info

Publication number
SG11201803781XA
SG11201803781XA SG11201803781XA SG11201803781XA SG11201803781XA SG 11201803781X A SG11201803781X A SG 11201803781XA SG 11201803781X A SG11201803781X A SG 11201803781XA SG 11201803781X A SG11201803781X A SG 11201803781XA SG 11201803781X A SG11201803781X A SG 11201803781XA
Authority
SG
Singapore
Prior art keywords
international
cells
progenitor cells
pennsylvania
johnson
Prior art date
Application number
SG11201803781XA
Inventor
Ian Harris
Jing Cao
Nadine Sophia Dejneka
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of SG11201803781XA publication Critical patent/SG11201803781XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48Reproductive organs
    • A61K35/51Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48Reproductive organs
    • A61K35/50Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau R.:54i (43) International Publication Date ..... ....r .„,,,i 8 June 2017 (08.06.2017) IN I PO I PCT ID Hit (10) WO International 2017/095991 111111111111111111111111111111111111111111111111111111111111111111111111111111 Publication Al Number (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 5/071 (2010.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/US2016/064336 DO, DZ, EC, EE, EG, ES, FE GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 1 December 2016 (01.12.2016) KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 62/263,463 4 December 2015 (04.12.2015) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: JANSSEN BIOTECH, INC. [US/US]; kind of regional protection available): ARIPO (BW, GH, 800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (US). TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors: HARRIS, Ian; 1400 McKean Road, Spring TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, House, Pennsylvania 19477 (US). CAO, Jing; 1400 McK- LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, can Road, Spring House, Pennsylvania 19477 (US). DE- SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, JNEKA, Nadine Sophia; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: (74) Agents: SHIRTZ, Joseph F. et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jer- — as to applicant's entitlement to apply for and be granted a sey 08933 (US). patent (Rule 4.170) [Continued on next page] (54) Title: TREATMENT OF RETINAL DEGENERATION USING PROGENITOR CELLS (57) : Methods and compositions for treating and re- ducing retinal degeneration using progenitor cells and condi- from tioned media progenitor cells, such as postpartum-de- **** rived cells are disclosed. Genetic factors and receptors ex - I I * * pressed by the progenitor cells that aid in protection of retinal 100 ' . cells and inhibition of apoptosis of retinal cells such as ****n.s. cells are also disclosed. photoreceptor 171) > 80- a) co to • 60- o , 0 40 0 11111 • 1111 E F 20- Nk . Vi kG 0 1\ e lk GO GS G. GO 54 S4 o_0 5 a 0S7 0 _0 k e 03S 4 Q\" \) \ ` - ‘Y` - \t - l‘ ikk 1\ 9- 0 9- \0\" \t\"(` ` vr ve \ ** 0 11 / 4 - .0 1 / 4 4 ‘.4 ‘.0 ‘ 1,4 0.9 ., cp , e s , o 1 / 4 2,S e\ 0 ,,,,, ,-, .4t • CO S3 : 3 •CA 13 •0 \ te t ee S %N. aG cy ci, .#0 . 0 0 0 __ %., 40 3e2P s y r car Cr .0 * s yew Il O\ O\ un FIG. 1 C\ C IN Il C ei O WO 2017/095991 Al MIDEDIMOMMIDIROMMIMINECIMMOVOIMIE — as to the applicant's entitlement to claim the priority of — with sequence listing part of description (Rule 5.2(a)) the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3))
SG11201803781XA 2015-12-04 2016-12-01 Treatment of retinal degeneration using progenitor cells SG11201803781XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562263463P 2015-12-04 2015-12-04
PCT/US2016/064336 WO2017095991A1 (en) 2015-12-04 2016-12-01 Treatment of retinal degeneration using progenitor cells

Publications (1)

Publication Number Publication Date
SG11201803781XA true SG11201803781XA (en) 2018-06-28

Family

ID=58797699

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803781XA SG11201803781XA (en) 2015-12-04 2016-12-01 Treatment of retinal degeneration using progenitor cells

Country Status (15)

Country Link
US (1) US20170157179A1 (en)
EP (1) EP3384009A4 (en)
JP (1) JP2019501888A (en)
KR (1) KR20180088713A (en)
CN (1) CN108291199A (en)
AR (1) AR106913A1 (en)
AU (1) AU2016365312A1 (en)
BR (1) BR112018011278A2 (en)
CA (1) CA3007198A1 (en)
MX (1) MX2018006729A (en)
PH (1) PH12018501045A1 (en)
RU (1) RU2018122461A (en)
SG (1) SG11201803781XA (en)
TW (1) TW201729819A (en)
WO (1) WO2017095991A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
KR102224115B1 (en) 2020-01-10 2021-03-09 경북대학교병원 Structure for retinal cell culture using 3D bioprinting and Uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001855A (en) * 1998-01-02 1999-12-14 Hoffman-La Roche Inc. Thiazole derivatives
US20010041670A1 (en) * 1999-12-06 2001-11-15 Ronit Simantov Thrombospondin-binding region of histidine-rich glycoprotein and method of use
BR0211604A (en) * 2001-08-01 2004-08-24 Merck Patent Gmbh Integrin inhibitors for the treatment of eye disease
US8790637B2 (en) * 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
EP1641915B1 (en) * 2003-06-27 2016-07-27 DePuy Synthes Products, Inc. Repair and regeneration of ocular tissue using postpartum-derived cells
CA2705541C (en) * 2007-11-15 2018-09-11 The Feinstein Institute For Medical Research Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using mfg-e8
JP6106159B2 (en) * 2011-05-09 2017-03-29 アレグロ ファーマシューティカルズ インコーポレイテッドAllegro Pharmaceuticals,Inc. Pharmaceutical composition comprising RG-cysteic acid peptide
WO2013184976A2 (en) * 2012-06-06 2013-12-12 Northwestern University Compositions and methods for antigen-specific tolerance
MX2017007953A (en) * 2014-12-16 2018-02-09 Janssen Biotech Inc Treatment of retinal degeneration using progenitor cells.

Also Published As

Publication number Publication date
US20170157179A1 (en) 2017-06-08
MX2018006729A (en) 2018-11-09
JP2019501888A (en) 2019-01-24
EP3384009A4 (en) 2019-06-12
WO2017095991A1 (en) 2017-06-08
EP3384009A1 (en) 2018-10-10
CN108291199A (en) 2018-07-17
BR112018011278A2 (en) 2018-11-21
RU2018122461A (en) 2020-01-13
AR106913A1 (en) 2018-02-28
KR20180088713A (en) 2018-08-06
PH12018501045A1 (en) 2019-01-28
TW201729819A (en) 2017-09-01
AU2016365312A1 (en) 2018-05-24
CA3007198A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
SG11201803593QA (en) Engineered nucleic-acid targeting nucleic acids
SG11201809649WA (en) Macromolecule analysis employing nucleic acid encoding
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201908391XA (en) Methods for modulating an immune response
SG11202000274RA (en) Oligonucleotide compositions and methods thereof
SG11201810179RA (en) Novel crispr enzymes and systems
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201806398YA (en) Optimized factor viii genes
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201908560SA (en) Heterocyclic compounds useful as dual atx/ca inhibitors
SG11201807269PA (en) Filamentous fungal biomats, methods of their production and methods of their use
SG11201804070XA (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201809700YA (en) Gdf15 fusion proteins and uses thereof
SG11201906319XA (en) Compositions and methods for the depletion of cd137+ cells
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
CA3025288C (en) Reduced misting alkaline and neutral cleaning, sanitizing, and disinfecting compositions via the use of high molecular weight water-in-oil emulsion polymers
SG11201811554SA (en) Antisense oligonucleotides for modulating htra1 expression
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201809751XA (en) Egfr inhibitor compounds
SG11201809531SA (en) BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF
SG11201803918VA (en) Production of steviol glycosides in recombinant hosts